I N T R O D U C T I O N

While the demand for minimally invasive

procedure treatments increases, the fillers

market is facing the publication of concer-

ning reports of immediate or late reactions

to Hyaluronic Acid (HA) fillers or other che-

mically based filling substances. The pa-

tients and the scientific community itself are

trending to natural and biocompatible der-

mal fillers as a safe and effective solution to

avoid adverse outcomes.

In response to the physician and patient

need, Advanced Aesthetic Technologies, Inc.

(AAT), a Boston, MA USA based company,

employing bio-technologies in the aesthetic

medical field, has launched Algeness®, the

100% natural and biodegradable injectable

implant, the culmination of 10 years of scien-

tific and clinical research.

W H A T I S A L G E N E S S ® ?

Algeness® is a biomaterial resulting from a sophi­

sticated manufacturing process consisting of a

purified agarose gel (polysaccharide), derived

from the purification of Agar­Agar processed

from red algae. Totally biocompatible to the

human body and absorbable, Algeness®, does not

contain cross­linked synthetic chemicals (BBDE

or PEG) associated with Hyaluronic acid (HA)

fillers and thus is 100% natural. The molecular

and biophysical properties of Algeness® make it

a breakthrough in the filler’s injection technology.

For the first time in aesthetic medicine history, a

100% natural, biodegradable and mouldable filler is

available to the aesthetic market for a more defined

youthful look.

Algeness agarose gel structure

Agarose is an hydrocolloid molecule water is contained in its structure

A G A R O S E M O L E C U L E

OH

OH HOn

H OO

OO

O

OH

OH

W H A T I S T H E S C I E N C E B E H I N D

A L G E N E S S ® A L L N A T U R A L B I O D E G R A D A B L E I M P L A N T ?

Algeness® is the culmination of 10 years of

scientific and clinical research to find the most

natural, biocompatible material to fill wrinkles

and compensate for volume loss in facial soft

tissues. Extensive research has been conducted

to master the correlation of the agarose struc-

ture and the physiological response; in fact,

utilizing different concentrations of agarose, it

was possible to obtain various three dimensio-

nal structures that interacted differently with

the vital and functional parameters of the cell.

Algeness® agarose is derived from the purifica-

tion of Agar-Agar, which in turn is derived from

red algae of the genus of gelidium.

Agarose which is h ighly purified is free of any

protein, a source for most bacteria, making it

highly biocompatible. Formulations of agarose

form stable gels with small amounts of material

(1% of agarose and 99% saline water making the

product able to be shaped for a more defined

natural look.

Chemically, agarose is a polysaccharide of a long

chain of disaccharide units formed by two rings

of 6 atoms. On each ring there is one oxygen and

5 Carbon atoms and only one OH group.

The agarose, being chemically inert does not

bind ions and does not precipitate when injec-

ted subcutaneously. Being free from toxicity to

micro-organisms and free from impurities, Alge-

ness® is well tolerated within the human body.

This production process is only achieved by a

limited number of highly specialized facilities.

They have the rights to international patents to

produce highly purified, high quality agarose

under rigid physical-chemical, and bacteriolo-

gical controls, as well as quality standards of

ISO 13485 and ISO 9001

W H A T A R E T H E B E N E F I T S O F A L G E N E S S ®

A L L N A T U R A L V O L U M I Z I N G B I O D E G R A D A B L E I M P L A N T ?

n Hydrocolloid gel 100% biocompatible

and biodegradable

n Immediate volumizing: “What you see

is what you get” The physician and the

patient can see and evaluate the result

of the injection immediately after the

procedure.

n No need to wait to see the hydrophi-

lic reaction associated with all HA fillers

that can take 2-4 weeks for the full

effect to be realized.

n Free of solvents and chemicals; all

natural.

n Long lasting results remaining over

12 months proven by clinical studies.

n Non allergenic; Algeness® offers ex-

cellent tolerability and biocompatibility

with a negligible immunological reaction.

n Minimal irritation & inflammation

due to the absence of foreign body

reactions

n Extremely low migration, the product

stays where it has been injected with

excellent persistence.

A L G E N E S S ® : A C O M P L E T E R A N G E O F 1 0 0 %

N A T U R A L F I L L E R S F O R F A C E R E J U V E N A T I O N

A G A R O S E M O L E C U L E

OH

OH HOn

H OO

OO

O

OH

OH

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

••

ALGENESS® LD 1%

Indications

Tear trough

Lips

Depth of injection:

subdermal

ALGENESS® HD 1.5%

Indications

Marionette lines,

wrinkles and furrows

Lip augmentation

and contouring

Oral commissure

Oro-mandibular folds

Depth of injection:

subdermal

ALGENESS® VL 2.5%

Indications

Medium-deep volumizing

Wrinkles, furrows and folds

Cheeks, jawline and chin

Nasolabial folds

Non-surgical rhinoplasty

Depth of injection:

Subdermal

Subcutaneous

ALGENESS® DF 3.5%

Indications

Deep volumetric filling

Cheeks, jawline and chin

Malar-zygomatic arch

Submalar

Depth of injection:

Subcutaneous

Supraperiosteal

Agarose (High density)

Deep sub-dermal Agarose (High density)

hypo-dermis and supra peri-osteal

S U P E R F I C I A LH Y P O D E R M I S

M U S C L E

D E R M I S

D E E P H Y P O D E R M I S

B O N E

3,5%

2,5% Agarose (Low density)Sub-dermal

1,5%A L G E N E S S

F I L L E R S

D E P T H

O F I N J E C T I O N

1% Agarose (Low density)Sub-dermal

A L G E N E S S ® S C I E N T I F I C R E S E A R C H

Currently there are 3 studies that were published

and there are a number of unpublished studies

executed on the new Algeness® 3.5% DF.

Wake Forest University in the United

States performed animal studies which

were completed in 2013 and 2014 with the

2.5% Algeness VL and the 3.5% Algeness

DF compared to Restylane, Juvederm and

Radiesse. The Wake Forest comparative

study showed that after 6 months 2.5%

and 3.5% performed better compared to

the other fillers, showing Algeness® lasted

longer, did not show unpredictable changes

due to inflammatory reactions or water

absorption, and exhibited less migration.

Four clinical studies were conducted in

Italy and Denmark in 2006/2007 where

Algeness® performed well with minimal

side effects and no serious problems were

reported. The effects of Algeness® lasted a

minimum of 6 months but was not compared

directly to Restylane or other filler materials.

These studies demonstrated the safety and

efficacy of Algeness® fillers. Algeness® HD

was extensively studied in the lips and was

found to be very effective with no reports of

adverse reactions.

Dr. Giovanni Montealegre, Professor of

Plastic Surgery at the National University of

Colombia, in Bogota, completed a 50 subject

study to evaluate the safety and efficacy of

Algeness® for the correction of nasolabial

folds in comparison to Juvederm. Both

Juvederm and Algeness® have similar and

comparable effects on safety and duration.

Algeness® offers excellent tolerability and

biocompatibility, is safe, natural and has a

negligible immunological reaction. Over the

first six months of observations, the results

are comparable with Juvederm.

In 2016 a 30 subject study of the volumizing

effects of Algeness® and Voluma will

commence in Belgium with Dr. Joan

Vandeputte, in Italy, Dr. Giovanni Salti, and in

Germany with Dr. Tatjana Pavicic.

Also started in 2016, is a prospective,

randomized, within-subject controlled study

of the effectiveness and safety of Algeness®

VL 2,5% Natural Agarose Subdermal Filler

Injectable Gel versus Restylane Perlane™

Injectable Gel, for the correction of moderate

and severe nasolabial folds. The principal

investigator is Nicolo Scuderi, MD, Professor

at University of Rome.

Q&AQ. What is the difference with

other fillers?

A. Unlike all other fillers,

Ageness® is 100% natural and

biodegradable. Algeness®

achieves its volumizing youth-

ful effects without the require-

ment of any added chemicals,

solvents or cross-linked agents

and is completely and safely

absorbed over time by the bo-

dy’s natural mechanisms.

Q. What areas could be proble-

matic using Algeness®?

A. Never inject Algeness® su-

perficially. It is strongly recom-

mended not to use Algeness®

fillers in the periorbital area.

Q. Into which layers of the

skin is it possible to inject

Algeness®?

A. The higher concentration

Algeness® biodegradable

implant should be injected

deeply and never superficially.

We therefore suggest that the

VL and DF only be used in the

subdermal, subcutaneous or

supraperiosteal spaces.

Q. Is there a difference in the

injecting technique between

Algeness® and HA?

A. There is a slight difference

in the injectability of HA versus

Algeness® due to the difference

in density of the material and

the depth of the injection.

Algeness® is injected deeply

and slowly. A thorough mas-

sage is performed to mold the

product, avoid formation of

lumps and obtain the desired

immediate result.

Q. Is it possible to inject

Algeness® in an area where

Radiesse (or a similar filler) was

injected previously?

A. We see no reason why

Algeness® cannot be used in

an area where other injectables

have been injected. Howe-

ver, this needs to be studied

further.

Q. Is it painful?

A. All injections cause a sense

of pain; however, the physician

may decide to apply anesthetic

cream to the injection site to

numb the area.

Q. What kind of result can the

patient expect?

A. Algeness® subcutaneous fil-

ler is able to achieve a youthful

and natural look by filling-out

lines around the mouth, the na-

so-labial fold as well as crow’s

feet and forehead wrinkles. It

can also re-plump your lips and

add volume and lift to your

cheeks.

Q. How long will it last?

A. Algeness® corrective effects

typically last for about 12 mon-

ths or longer depending on the

injection amount and depth of

injection.

Q. What are the side effects?

A. Depending on the area

injected, the procedure is

relatively painless, although

there may be some mild dis-

comfort during treatments to

the sensitive nose or lip areas.

There may be some redness

around the site of injection for

1-2 days. Thanks to its unique

all natural bio-compatibility,

post-treatment allergic reac-

tions are minimized.

Q. What is the recovery time?

A. Treatment times may vary

from 20-25 minutes, depen-

ding on the correction level

requested by the patient. The

recovery time can be from

a few hours to several days

depending on the area treated.

Usually, patients receiving

Algeness® treatments return to

normal activities straight after

injection.

A G A R O S E M O L E C U L E

OH

OH HOn

H OO

OO

O

OH

OH

IMMEDIATE VOLUMIZING:

[ WHAT YOU SEE

IS WHAT YOU GET ]

THE PHYSICIAN

AND THE PATIENT

CAN SEE AND EVALUATE

THE RESULT

OF THE INJECTION

IMMEDIATELY

AFTER THE PROCEDURE.

HYDROCOLLOID GEL

BIOCOMPATIBLE

AND BIODEGRADABLE.

100%

•

•

•

•

•

•

•

•

•

••

•

•

•

•

•

••

1.Amedee J, Bareille R, Jeandot R, Bordenave L, Remy M, Rouais F, Baquey C: Evaluation of cell colonization on biomaterials: preventing cell attachment to plastic containers. Biomaterials. 1994; 15 (12): 1029-31. 2.Athanasiou KA, Shah AR, Hernandez RJ, LeBaron RG: Basic science of articular cartilage repair. Clin Sports Med. 2001; 20 (2): 223-47.3.Aung T, Inoue K, Kogire M, Sumi S, Fujisato T, Gu YJ, Shinohara S, Hayashi H, Doi R, Imamura M: Improved insulin release from a bioartificial pancreas using mesh-reinforced polyvinyl alcohol hydrogel tube: immobilization of islets in agarose gel. Transplant Proc. 1994; 26 (2): 790-1. 4.Balgude AP, Yu X, Szymanski A, Bellamkonda RV: Agarose gel stiffness determines rate of DRG neurite extension in 3D cultures. Biomaterials. 2001; 22 (10): 1077-84.5.Bellamkonda R, Ranieri JP, Bouche N, Aebischer P: Hydrogel-based three-di-mensional matrix for neural cells. J Biomed Mater Res. 1995; 29: 663-71.6.Belpaeme K, Delbeke K, Zhu L, Kirsch-Volders M: Cytogenetic studies of PCB77 on brown trout (Salmo trutta fario) using the micronucleus test and the alkaline comet assay. Mutagenesis. 1996; 11 (5): 485-92. 7.Benjegard SA, Sauret V, Bernhardt P, Wangberg B, Ahlman H, Fors-sell-Aronsson E: Evaluation of three gamma detectors for intraoperative detection of tumors using 111In-labeled radiopharmaceuticals. J Nucl Med. 1999; 40 (12): 2094-101. 8.Berge V, Johnson E, Hogasen K: Clusterin and the terminal complement pathway synthesized by human umbilical vein endothelial cells are closely linked when detected on co-cultured agarose beads. APMIS. 1997; 105 (1): 17-24. 9.Bergstrom P, Johnsson A, Cavallin-Stahl E, Bergenheim T, Henriksson R: Effects of cisplatin and amphotericin B on DNA ad-duct formation and toxicity in malignant glioma and normal tissues in rat. Eur J Cancer. 1997; 33 (1): 153-9.10.Borkenhagen M, Clemence JF, Sigrist H, Aebischer P: Three-dimensional extra-cellular matrix engineering in the nervous system. J Biomed Mater Res. 1998; 40 (3): 392-400. 11.Bumgardner JD, Lucas LC: Corrosion and cell culture evaluations of nic-kel-chromium dental casting alloys. J Appl Biomater. 1994; 5 (3): 203-13. 12.Bux J, Dickmann JO, Stockert U, Mueller-Eckhardt C: Influence of granulo-cyte antibodies on granulocyte function. Vox Sang. 1993; 64 (4): 220-5. 13.Cao X, Shoichet MS: Photoimmobiliza-tion of biomolecules within a 3-dimensio-nal hydrogel matrix. J Biomater Sci Polym Ed. 2002; 13 (6): 623-36.14.Cerda H, Delincee H, Haine H, Rupp H: The DNA ‘comet assay’ as a rapid scree-ning technique to control irradiated food. Mutat Res. 1997; 375 (2): 167-81.

15.Chen ZJ, Broaddus WC, Viswanathan RR, Raghavan R, Gillies GT: Intraparen-chymal drug delivery via positive-pres-sure infusion: experimental and modeling studies of poroelasticity in brain phantom gels. IEEE Trans Biomed Eng. 2002; 49 (2): 85-96. 16.Cho YS, Hong ST, Choi KH, Chang YH, Chung AS: Chemopreventive Activity of Porphyrin Derivatives Against 6-Sul-fooxymethylbenzo[a]pyrene Mutagenicity. Asian Pac J Cancer Prev. 2000; 1 (4): 311-7. 17.Christie DJ, Lennon SS, Drew RL, Swinehart CD: Cefotetan-induced immu-nologic thrombocytopenia. Br J Haematol. 1988; 70 (4): 423-6. 18.Ciaccio PJ, Gicquel E, O’Neill PJ, Scribner HE, Vandenberghe YL: Investigation of the positive response of ethyl acrylate in the mouse lymphoma genotoxicity assay. Toxicol Sci. 1998; 46 (2): 324-32. 19.Cook JL, Williams N, Kreeger JM, Pea-cock JT, Tomlinson JL: Biocompatibility of three-dimensional chondrocyte grafts in large tibial defects of rabbits. Am J Vet Res. 2003; 64 (1): 12-20. 20.Dandurand RJ, Wang CG, Laberge S, Martin JG, Eidelman DH: In vitro allergic bronchoconstriction in the brown Norway rat. Am J Respir Crit Care Med. 1994; 149 (6): 1499-505. 21.De Boeck M, Kirsch-Volders M: Nereis virens (Annelida: Polychaeta) is not an adequate sentinel species to assess the genotoxic risk (comet assay) of PAH exposure to the environment. Environ Mol Mutagen. 1997; 30 (1): 82-90. 22.De Graaf M, Van Veen IC, Van Der Meulen-Muileman IH, Gerritsen WR, Pinedo HM, Haisma HJ: Cloning and characterization of human liver cytosolic -glycosidase. Biochem J. 2001; 356: 907-910.23.Dillon GP, Yu X, Sridharan A, Ranieri JP, Bellamkonda RV: The influence of physical structure and charge on neurite extension in a 3D hydrogel scaffold. J Biomater Sci Polym Ed. 1998; 9 (10): 1049-69.24.Dixit M, Yang JL, Poirier MC, Price JO, Andrews PA, Arteaga CL: Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epider-mal growth factor antisense RNA. J Natl Cancer Inst. 1997; 89 (5): 365-73. 25.Dupuy B, Cadic C, Gin H, Baquey C, Dufy B, Ducassou D: Microencapsulation of isolated pituitary cells by polyacryla-mide microlatex coagulation on agarose beads. Biomaterials. 1991; 12 (5): 493-6. 26.Enzmann H, Wiemann C, Ahr HJ, Schluter G: Damage to mitochondrial DNA induced by the quinolone Bay y 3118 in embryonic turkey liver. Mutat Res. 1999; 425 (2): 213-24. 27.Fernández-Cossío S, León-Mateos A, Sampedro FG, Oreja MT: Biocompa-tibility of agarose gel as a dermal filler: histologic evaluation of subcutaneous implants. Plast Reconstr Surg. 2007; 120 (5): 1161-9.

28.Ferrero M, Castano A, Gonzalez A, Sanz F, Becerril C: Characterization of RTG-2 fish cell line by random amplified polymorphic DNA. Ecotoxicol Environ Saf. 1998; 40 (1-2): 56-64. 29.Flowers L, Bleczinski WF, Burczynski ME, Harvey RG, Penning TM: Disposi-tion and biological activity of benzo[a]pyrene-7,8-dione. A genotoxic metabolite generated by dihydrodiol dehydrogenase. Biochemistry. 1996; 35 (42): 13664-72. 30.Giorgi L, Fanfani E, Paternostro E, Trovati F, Falchetti A, Novelli GP: Imme-diate-early genes expression in spinal cord as related to acute noxious stimulus. Int J Clin Pharmacol Res. 1997; 17 (2-3): 59-61. 31.Gu Y, Tabata Y, Kawakami Y, Balamu-rugan AN, Hori H, Nagata N, Satake A, Cui W, Qi M, Misawa Y, Toma M, Miyamoto M, Nozawa M, Inoue K: Development of a new method to induce angiogenesis at subcutaneous site of streptozotocin-in-duced diabetic rats for islet transplan-tation. Cell Transplant. 2001; 10 (4-5): 453-7. 32.Hoemann CD, Sun J, Légaré A, McKee MD, Ranger P, Buschmann MD: A thermosensitive polysaccharide gel for cell delivery in cartilage repair. 47th Ann Meeting Orthopaedic Soc. Feb. 25-28, 2001, San Francisco, California, Poster session 0626 33.Hutmacher DW, Goh JC, Teoh SH: An introduction to biodegradable materials for tissue engineering applications. Ann Acad Med Singapore. 2001; 30 (2): 183-91.

34.Iwata H, Kobayashi K, Takagi T, Oka T, Yang H, Amemiya H, Tsuji T, Ito F: Feasibility of agarose microbeads with xenogeneic islets as a bioartificial pancreas. J Biomed Mater Res. 1994; 28 (9): 1003-11. 35.Iwata H, Takagi T, Amemiya H, Shimizu H, Yamashita K, Kobayashi K, Akutsu T: Agarose for a bioartificial pancreas. J Biomed Mater Res. 1992; 26: 967-77. 36.Iwata H, Takagi T, Kobayashi K, Oka T, Tsuji T, Ito F: Strategy for develo-ping microbeads applicable to islet xenotransplantation into a spontaneous diabetic NOD mouse. J Biomed Mater Res. 1994; 28 (10): 1201-7. 37.Iwata H, Takagi T, Kobayashi K, Yang H, Ito F: Immunoisolative effectiveness and limitation of agarose in a bioartificial pancreas. Transplant Proc. 1994; 26 (2): 789. 38.Kawakami Y, Inoue K, Hayashi H, Wang WJ, Setoyama H, Gu YJ, Imamura M, Iwata H, Ikada Y, Nozawa M, Miyazaki J: Subcutaneous xenotransplantation of hybrid artificial pancreas encapsulating pancreatic B cell line (MIN6): functional and histological study. Cell Transplant. 1997; 6 (5): 541-5. 39.Kawakami Y, Inoue K, Tun T, Hayashi H, Setoyama H, Gu YJ, Cui WX, Imamura M, Iwata H, Ikada Y: Prolonged effect of troglitazone (CS-045) on xenograft survival of hybrid artificial pancreas. Cell

Transplant. 1997; 6 (5): 547-50. 40.Kisiday J, Jin M, Kurz B, Hung H, Semino C, Zhang S, Grodzinsky AJ. Self-assembling peptide hydrogel fosters chondrocyte extracellular matrix produc-tion and cell division: implications for cartilage tissue repair. Proc Natl Acad Sci U S A. 2002; 99 (15): 9996-10001. 41.Kopjar N, Garaj-Vrhovac V: Application of cytogenetic endpoints and Comet as-say on human lymphocytes treated with vincristine in vitro. Neoplasma. 2000; 47 (3): 162-7. 42.Kuijpers AJ, van Wachem PB, van Luyn MJ, Engbers GH, Krijgsveld J, Zaat SA, Dankert J, Feijen J: In vivo and in vitro release of lysozyme from cross-linked gelatin hydrogels: a model system for the delivery of antibacterial proteins from prosthetic heart valves. J Control Release. 2000; 67 (2-3): 323-36.43.Manderville RA, Wade Calcutt M, Dai J, Park G, Gillman IG, Noftle RE, Mo-hammed AK, Dizdaroglu M, Rodriguez H, Akman SA: Stoichiometric preference in copper-promoted oxidative DNA damage by ochratoxin A. J Inorg Biochem. 2003; 95 (2-3): 87-96. 44.Manev V, Grigorov M, Penkova K, Chaushev A, Ramshev K, Topalov I, Lese-va N, Ivanov G, Ivanova I, Nedialkova V: The cellular immunity indices of patients with a rheumatic heart defect. Vutr Boles. 1990; 29 (6): 52-7. 45.Manzke O, Tesch H, Diehl V, Bohlen H: Single-step purification of bispecific monoclonal antibodies for immunothe-rapeutic use by hydrophobic interaction chromatography. J Immunol Methods. 1997; 208 (1): 65-73. 46.Marczylo T, Arimoto-Kobayashi S, Hayatsu H: Protection against Trp-P-2 mutagenicity by purpurin: mechanism of in vitro antimutagenesis. Mutagenesis. 2000; 15 (3): 223-8. 47.Marrot L, Agapakis-Causse C: Diffe-rences in the photogenotoxic potential of two fluoroquinolones as shown in diploid yeast strain (Saccharomyces cerevisae) and supercoiled plasmid DNA. Mutat Res. 2000; 468 (1): 1-9. 48.Mauck RL, Seyhan SL, Ateshian GA, Hung CT: Influence of seeding density and dynamic deformational loading on the developing structure/function rela-tionships of chondrocyte-seeded agarose hydrogels. Ann Biomed Eng. 2002; 30 (8): 1046-56. 49.McCarty MF, Baker CH, Bucana CD, Fidler IJ: Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol. 2002; 21 (1): 5-10. 50.Méhul B, Corre C, Capon C, Bernard D, Schmidt R: Carbohydrate expression and modification during keratinocyte differen-tiation in normal human and reconstruc-ted epidermis. Exp. Dermatology. 2003; 12 (5): 537-45.51.Meilander NJ, Yu X, Ziats NP, Bel-lamkonda RV: Lipid-based microtubular drug delivery vehicles. J Control Release. 2001; 71 (1): 141-52. 52.Monteith DK, Vanstone J: Comparison

of the microgel electrophoresis assay and other assays for genotoxicity in the detection of DNA damage. Mutat Res. 1995; 345 (3-4): 97-103. 53.Navarrete MH, Carrera P, de Miguel M, de la Torre C: A fast comet assay variant for solid tissue cells. The assessment of DNA damage in higher plants. Mutat Res. 1997; 389 (2-3): 271-7. 54.Naziruddin B, Durriya S, Phelan D, Duffy BF, Olack B, Smith D, Howard T, Mohanakumar T: HLA antibodies present in the sera of sensitized patients awaiting renal transplant are also reactive to swine leukocyte antigens. Transplanta-tion. 1998; 66 (8): 1074-80. 55.O’Driscoll SW: Articular cartilage re-generation using periosteum. Clin Orthop. 1999; (367 Suppl): S186-203. 56.Ohgawara H, Miyazaki J, Karibe S, Tashiro F, Akaike T, Hashimoto Y: Embedded-culture of pancreatic beta-cells derived from transgenic mouse insulinoma as a potential source for xenotransplantation using a diffusion chamber. Cell Transplant. 1995; 4 (3): 307-13. 57.Ohgawara H: Strategies for im-munoisolation in islet transplantation: challenges for the twenty-first century. J Hepatobiliary Pancreat Surg. 2000; 7 (4): 374-9.58.Olbrich C, Bakowsky U, Lehr CM, Muller RH, Kneuer C: Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release. 2001; 77 (3): 345-55. 59.Park K, Shalaby W, Park H: Biodegra-dable hydrogels for drug delivery. CRC Press, 199360.Pini R, Giannazzo G, Di Bari M, Inno-centi F, Rega L, Casolo G, Devereux RB: Transthoracic three-dimensional echocar-diographic reconstruction of left and right ventricles: in vitro validation and compa-rison with magnetic resonance imaging. Am Heart J. 1997; 133 (2): 221-9. 61.Polyzois GL, Hensten-Pettersen A, Kullmann A: An assessment of the physical properties and biocompatibility of three silicone elastomers. J Prosthet Dent. 1994; 71 (5): 500-4. 62.Prevost P, Flori S, Collier C, Muscat E, Rolland E: Application of AN69 hydrogel to islet encapsulation. Evaluation in strep-tozotocin-induced diabetic rat model. Ann N Y Acad Sci. 1997; 831: 344-9. 63.Przybojewska B: Assessment of aniline derivatives-induced DNA damage in the liver cells of B6C3F1 mice using the alkaline single cell gel electrophoresis (‘comet’) assay. Cancer Lett. 1999; 147 (1-2): 1-4.64.Rahfoth B, Weisser J, Sternkopf F, Aigner T, von der Mark K, Brauer R: Transplantation of allograft chondrocytes embedded in agarose gel into cartilage defects of rabbits. Osteoarthritis Carti-lage. 1998; 6 (1): 50-65.65.Rickert D, Lendlein A, Kelch S, Fuhrmann R, Franke RP: Detailed evaluation of the agarose diffusion test in biocompatibility study with a microscopic

image analysis system. Effect of plasma sterilization on biocompatible of an improved photoset polymer. Biomed Tech (Berl). 2002; 47 (11): 285-9. 66.Rotter N, Aigner J, Naumann A, Planck H, Hammer C, Burmester G, Sittinger M: Cartilage reconstruction in head and neck surgery: comparison of resorbable polymer scaffolds for tissue engineering of human septal cartilage. J Biomed Mater Res. 1998; 42: 347-56. 67.Sallustio BC, Harkin LA, Mann MC, Krivickas SJ, Burcham PC: Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase-II-mediated bioactivation in the hepato-carcinogenicity of the parent ag-lycones? Toxicol Appl Pharmacol. 1997; 147 (2): 459-64.

68.Saxena S, Jha P, Farooq A: Purification and characterisation of an immuno-suppressive factor from normal human seminal plasma. J Reprod Immunol. 1988; 13 (2): 133-46. 69.Schmalz G, Hoffmann M, Weis K, Schweikl H: Influence of albumin and collagen on the cell mortality evoked by zinc oxide-eugenol in vitro. J Endod. 2000; 26 (5): 284-7. 70.Sittinger M, Bujia J, Minuth WW, Hammer C, Burmester GR: Engineering of cartilage tissue using bioresorbable polymer carriers in perfusion culture. Biomaterials. 1994; 15 (6): 451-6. 71.Sittinger M, Perka C, Schultz O, Haupl T, Burmester GR: Joint cartilage regeneration by tissue engineering. Z Rheumatol. 1999; 58 (3): 130-5.72.Soparkar CN, Wong JF, Patrinely JR, Appling D: Growth factors embedded in an agarose matrix enhance the rate of porous polyethylene implant biointegra-tion. Ophthal Plast Reconstr Surg. 2000; 16 (5): 341-6.73.Soparkar CN, Wong JF, Patrinely JR, Davidson JK, Appling D: Porous polyethylene implant fibrovascularization rate is affected by tissue wrapping, aga-rose coating, and insertion site. Ophthal Plast Reconstr Surg. 2000; 16 (5): 330-6. 74.Tan X, Li S, Luo X, Zhou Y: Molecular mechanism of mutagenesis induced by aflatoxin B1 using a shuttle vector pSP189/mammalian cell system. Wei Sheng Yan Jiu. 1997; 26 (4): 271-7. 75.Tashiro H, Iwata H, Warnock GL, Ikada Y, Tsuji T: Application of agarose micro-capsules to allo-islet transplantation in a canine model. Transplant Proc. 1998; 30 (2): 498-9. 76.Tashiro H, Iwata H, Warnock GL, Takagi T, Machida H, Ikada Y, Tsuji T: Characterization and transplantation of agarose microencapsulated canine islets of Langerhans. Ann Transplant. 1997; 2 (3): 33-9. 77.Taylor SG, Osman N, McKenzie IFC, Sandrin MS: Reduction of a-Gal expres-sion by relocalizing a-galactosidase to the trans-Golgi network and cell surface. Glycobiology. 2002; 12 (11): 729-739.78.Thomas DC, Svoboda DL, Vos JM,

Kunkel TA: Strand specificity of mutage-nic bypass replication of DNA containing psoralen monoadducts in a human cell extract. Mol Cell Biol. 1996; 16 (5): 2537-44. 79.Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF: Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen. 2000; 35 (3): 206-21. 80.Uludag H, De Vos P, Tresco PA: Techno-logy of mammalian cell encapsulation. Adv Drug Deliv Rev. 2000; 42 (1-2): 29-64.81.von Blomberg-van der Flier M, van der Burg CK, Pos O, van de Plassche-Boers EM, Bruynzeel DP, Garotta G, Scheper RJ: In vitro studies in nickel allergy: diagnos-tic value of a dual parameter analysis. J Invest Dermatol. 1987; 88 (4): 362-8. 82.Wang H, Yi S, Xiao Y, Li D, Qi J, Fu J: Establishment of human amnion cell mutagenesis system by using a shuttle vector pS189. Hua Xi Yi Ke Da Xue Bao. 1996; 27 (4): 372-7. 83.Wang N, Wu XS: Preparation and characterization of agarose hydrogel nanoparticles for protein and peptide drug delivery. Pharm Dev Technol. 1997; 2 (2): 135-42. 84.Wang W, Gu Y, Miyamoto M, Hori H, Nagata N, Balamurugan AN, Touma M, Sakurai T, Inoue K: Effect of basic fibroblast growth factor on insulin secre-tion from microencapsulated pancreatic islets: an in vitro study. Cell Transplant. 2001; 10 (4-5): 465-71. 85.Wang W, Gu Y, Tabata Y, Miyamoto M, Hori H, Nagata N, Touma M, Balamu-rugan AN, Kawakami Y, Nozawa M, Inoue K: Reversal of diabetes in mice by xenotransplantation of a bioartificial pancreas in a prevascularized subcu-taneous site. Transplantation. 2002; 73 (1): 122-9. 86.Wang WJ, Inoue K, Hayashi H, Aung T, Tun T, Gu YJ, Kaji H, Echigo Y, Kato M, Doi R, Setoyama H, Kawakami Y, Imamura M, Maetani S, Morikawa N, Iwata H, Ikada Y, Miyazaki JI: Efficacy of microencapsu-lation of a pancreatic B-cell line (MIN6) in an agarose/PSSa microbead as a bioartificial pancreas. Transplant Proc. 1996; 28 (2): 1094-6. 87.Winton HL, Wan H, Cannell MB, Thompson PJ, Garrod DR, Stewart GA, Robinson C: Class specific inhibition of house dust mite proteinases which cleave cell adhesion, induce cell death and which increase the permeability of lung epithelium. Br J Pharmacol. 1998; 124 (6): 1048-59. 88.Xu B, Iwata H, Miyamoto M, Balamu-rugan AN, Murakami Y, Cui W, Imamura M, Inoue K: Functional comparison of the single-layer agarose microbeads and the developed three-layer agarose microbeads as the bioartificial pancreas: an in vitro study. Cell Transplant. 2001; 10 (4-5): 403-8. 89.Yang H, Iwata H, Shimizu H, Takagi T,

Tsuji T, Ito F: Comparative studies of in vitro and in vivo function of three different shaped bioartificial pancreases made of agarose hydrogel. Biomaterials. 1994; 15 (2): 113-20. 90.Yu X, Dillon GP, Bellamkonda RB: A laminin and nerve growth factor-laden three-dimensional scaffold for enhanced neurite extension. Tissue Eng. 1999; 5 (4): 291-304.91.Yusuf AT, Vian L, Sabatier R, Cano JP: In vitro detection of indirect-acting geno-toxins in the comet assay using Hep G2 cells. Mutat Res. 2000; 468 (2): 227-34. 92.Kablik J, Monheit GD, Yu L, Chang G, Gershkovich J: Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg. 2009; 35 Suppl 1: 302-12. Review93.Beasley KL, Weiss MA, Weiss RA: Hyaluronic acid fillers: a comprehensive review. Facial Plast Surg. 2009; 25 (2): 86-94. Review94.Gold M: The science and art of hya-luronic acid dermal filler use in esthetic applications. J Cosmet Dermatol. 2009; 8 (4): 301-7. Review95.Beer K: Dermal fillers and combi-nations of fillers for facial rejuvenation. Dermatol Clin. 2009; 27 (4): 427-32, Review96.Carruthers J, Cohen SR, Joseph JH, Narins RS, Rubin M: The science and art of dermal fillers for soft-tissue augmen-tation. J Drugs Dermatol. 2009; 8 (4): 335-50. Review97.Sarnoff DS, Saini R, Gotkin RH: Comparison of filling agents for lip augmentation. Aesthet Surg J. 2008; 28 (5): 556-63. Review98.Brandt FS, Cazzaniga A: Hyaluronic acid gel fillers in the management of facial aging. Clin Interv Aging. 2008; 3 (1): 153-9. Review99.Bogdan Allemann I, Baumann L: Hya-luronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging. 2008; 3 (4): 629-34. Review100.Rohrich RJ, Ghavami A, Crosby MA: The role of hyaluronic acid fillers (Restylane) in facial cosmetic surgery: review and technical considerations. Plast Reconstr Surg. 2007; 120 (6 Suppl): 41S-54S. Review101.Motolese P: Agarose gel: long-lasting absorbable filler. U&U. 2005 (2).102.Scarano A, Carinci F, Piattelli A: Lip augmentation with a new filler (agarose gel): a 3-year follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 (2): e11-5103.Scarano A: Ringiovanimento dei tessuti molli periorali. Dent Clin. 2009; 2: 5-13

B I B L I O G R A P H Y

A d v a n c e d A e s t h e t i c Te c h n o l o g i e s , I n c

O n e B r o o k l i n e P l a c e , S u i t e 4 2 7 - B r o o k l i n e , M A 0 2 4 4 5

w w w . a l g e n e s s . c o m - i n f o @ a l g e n e s s . c o m